Opioid detox for Boca Raton — fentanyl-era protocols, buprenorphine done right.

RECO Island's Delray Beach campus sits 11 miles up Federal Highway from Mizner Park — 20 minutes from downtown Boca Raton. Opioid detox here is COWS-guided, buprenorphine-forward, and built for the fentanyl era, including low-dose and micro-induction protocols when clinically indicated. Small-census, physician-led, with direct in-house transition into residential treatment — no waitlists, no third-party handoffs.

For Boca Raton residents facing opioid dependence, RECO Island’s Delray Beach detox campus sits 11 miles up Federal Highway — a 20-minute drive from Mizner Park or Royal Palm Place, shorter than most local commutes. Proximity matters clinically. Medical opioid detox is not a one-way exit but the first stage of a longer treatment arc, and closeness to family, sponsors, and continuing-care providers correlates with better long-term outcomes.

Opioid withdrawal in the fentanyl era

Fentanyl and its analogs have materially changed opioid withdrawal management. Where heroin and prescription-opioid withdrawal followed a predictable arc — onset at 8 to 12 hours, peak at 36 to 72 hours, most acute symptoms resolving by day five to seven — fentanyl withdrawal emerges faster, hits harder, and is less predictable. Fentanyl’s lipophilicity produces variable tissue redistribution; adulterants including xylazine and nitazenes complicate the picture further, sometimes requiring alpha-2 agonist management for the sedative component of xylazine withdrawal.

The practical implication for induction: buprenorphine started at the traditional 12- to 24-hour mark on moderate withdrawal now carries a higher risk of precipitated withdrawal in fentanyl-exposed patients. Precipitated withdrawal — a severe, medication-induced worsening when a partial agonist displaces a full agonist from opioid receptors — undermines the therapeutic alliance and drives premature discharge. The medical team screens for fentanyl exposure at intake and adjusts induction timing and dosing accordingly, including low-dose or micro-induction protocols when clinically indicated.

The nursing model reflects the pharmacology: 24/7 RN coverage, physician on call, and COWS monitoring at fixed intervals through the first 72 hours. Opioid withdrawal does not carry the mortality risk of unmanaged alcohol or benzodiazepine withdrawal, but it is the withdrawal syndrome most responsive to competent bedside care.

COWS-guided buprenorphine induction

The Clinical Opiate Withdrawal Scale (COWS) is the assessment tool used to time induction. Eleven observable and self-reported domains — resting pulse, sweating, restlessness, pupil size, bone and joint aches, rhinorrhea and lacrimation, GI upset, tremor, yawning, anxiety, and gooseflesh — are scored and summed. Under 5 is no withdrawal; 5 to 12 mild; 13 to 24 moderate; 25 to 36 moderately severe; above 36 severe.

Standard induction begins when COWS crosses 11 to 13. Initial buprenorphine dose is 2 to 4 mg sublingual, reassessed at 60 to 90 minutes with additional 2 to 4 mg doses titrated to symptom control. Most patients reach a stable day-one dose between 8 and 16 mg. For fentanyl-exposed patients where standard induction risks precipitated withdrawal, low-dose induction — starting at 0.5 mg while the patient remains on their existing opioid, titrated over several days — or micro-induction protocols are the current addiction-medicine preference.

Comfort medications supplement rather than replace the induction: clonidine 0.1 to 0.2 mg for autonomic hyperarousal, loperamide for GI hypermotility, ondansetron for nausea, hydroxyzine for anxiety and insomnia, and non-benzodiazepine muscle relaxants for myalgia. NSAIDs address bone pain. The clinical target through day three is symptom control adequate for the patient to eat, sleep, and engage — not the elimination of every subjective discomfort, which drives over-medication.

Buprenorphine, methadone, or naltrexone — the MAT decision

Medication-assisted treatment for opioid use disorder has three evidence-based options, and the choice is made during the detox stay based on clinical picture, prior response, and continuing-care access. Buprenorphine continues as maintenance in most cases: partial-agonist ceiling effect reduces overdose risk, sublingual and extended-release injectable formulations (Sublocade) support adherence, and office-based prescribing keeps the patient in general medical care rather than a specialty silo.

Methadone remains the strongest evidence-based option for patients with high-dose or long-duration opioid use disorder, particularly those who have failed prior buprenorphine trials. Access requires enrollment in a federally regulated opioid treatment program, a real logistical factor in Palm Beach County. Extended-release naltrexone (Vivitrol) is the third option — an opioid antagonist, monthly intramuscular injection, requiring a documented 7 to 10 day opioid-free period before the first dose to avoid precipitated withdrawal.

The decision is clinical, not ideological. Motivational interviewing frames it as a shared choice, and the team walks through relapse risk, overdose risk, pregnancy considerations, and interactions with co-occurring psychiatric medications — sertraline or another SSRI for depression, quetiapine for mood or sleep, buspirone for anxiety, aripiprazole where indicated. CBT and contingency management run alongside the pharmacology; medication without a therapy framework has weaker outcomes than the two combined.

Naloxone education and the safety net

Every RECO Island opioid detox client, and at least one family member, receives naloxone education and a take-home prescription at discharge. This is standard of care, not optional programming. Post-detox mortality risk is concentrated in the first two to four weeks after discharge — tolerance has dropped, return-to-use is a real possibility, and the fentanyl-adulterated street supply means a pre-detox dose is now potentially lethal.

Naloxone (Narcan) is a competitive opioid receptor antagonist. Intranasal 4 mg is the standard community formulation; onset is 2 to 3 minutes, duration 30 to 90 minutes — often shorter than the offending opioid, particularly for fentanyl and its analogs. Families are taught to give the first dose, call 911, position the patient for airway protection, and repeat at 2 to 3 minute intervals if there is no response. Florida’s Good Samaritan provisions offer legal protection for callers.

Harm reduction is not in tension with abstinence-based treatment; it is a mortality intervention that keeps clients alive long enough for treatment to work. Naloxone distribution pairs with MAT continuation, warm handoffs to community prescribers, and family-communication protocols that surface early-warning signs before an overdose event.

Admission and the first 72 hours from Boca Raton

Admissions from Boca Raton typically begin with a phone screen with the admissions team — verifying insurance benefits, gathering a clinical history, and confirming that medical detox is the appropriate level of care under ASAM Criteria dimensions 1 through 6 (intoxication and withdrawal potential, biomedical conditions, emotional-cognitive-behavioral conditions, readiness to change, relapse potential, and recovery environment). Same-day or next-day admission is standard; there are no waitlists.

At admission, a physician performs a history and physical, medication reconciliation, and toxicology screen. Vital signs, ECG when indicated by prior stimulant use or QT-prolonging medications, and metabolic panels support safe pharmacological management. Psychiatric screening uses PHQ-9 for depression, GAD-7 for anxiety, and structured questions for trauma history and adult ADHD (ASRS), given the high co-occurrence rates between opioid use disorder and PTSD, major depressive disorder, and attention-related conditions. Concurrent psychiatric medications — SSRIs, SNRIs, mood stabilizers such as lithium, ADHD stimulants — are managed by the on-staff psychiatrist rather than paused reflexively.

From detox to residential — the in-house transition

Detox in isolation has poor outcomes. Patients discharged directly home from acute withdrawal management, without immediate continuing care, relapse at rates that make the detox admission itself clinically questionable. The structural answer at RECO Island is direct in-house transition — no waitlist, no discharge-and-re-admit, no third-party handoff. The same physician, therapist, and case manager who managed the detox continue into residential.

Residential layers evidence-based modalities: CBT for relapse prevention and cognitive restructuring, DBT skills groups for emotion regulation, EMDR or trauma-focused CBT for co-occurring PTSD, acceptance and commitment therapy (ACT) for values-based work, and motivational interviewing through individual sessions. For Boca Raton clients, discharge planning includes warm handoffs to local buprenorphine prescribers, outpatient therapists, and community recovery supports — 12-step, SMART Recovery, Refuge Recovery — near downtown Boca, Boca West, and Highland Beach. Follow-up appointments are scheduled before discharge, not after.

Serving residents of: Mizner Park, Royal Palm Place, Downtown Boca, Boca West, Highland Beach.